Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 14/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8938342 | 0.90 | MAP2 (0.58) | MAP2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL9034407 | 0.82 | ALDH1A1 (0.64) | MAP2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL8938321 | 0.81 | PTGS2 (0.52) | MAP2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL5790661 | 0.79 | MAP2 (0.55) | MAP2SIRT1 | |
| SCHEMBL5792859 | 0.79 | MAP2 (0.53) | MAP2KDM4EALDH1A1SIRT1MAPT | |
| SCHEMBL8938413 | 0.77 | CNR1 (0.45) | KDM4EALDH1A1MAPK1POLB | |
| SCHEMBL5793248 | 0.75 | MAP2 (0.48) | MAP2KDM4EALDH1A1 | |
| SCHEMBL11403058 | 0.75 | MAP2 (1.00) | MAP2KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL9033744 | 0.75 | MAPK3 (0.43) | MAP2KDM4EALDH1A1MAPK1POLB | |
| SCHEMBL9040770 | 0.74 | MCL1 (0.44) | MAP2KDM4EALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5527819-A | TREATING AIDS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | claimed |
| EP-0686148-A4 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO INC (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0686148-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO. INC. (US) | 1995-12-13 | — | — | EP | claimed |
| EP-0678508-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1995-10-25 | — | — | EP | claimed |
| WO-1994019321-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1993005020-A1 | INDOLES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | claimed |
| EP-0530907-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1993-03-10 | — | — | EP | claimed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-113453679-A | Targeted protein degradation | C4医药公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-108136044-B | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-5527819-A | TREATING AIDS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0686148-A4 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO INC (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0686148-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO. INC. (US) | 1995-12-13 | — | — | EP | disclosed |
| EP-0678508-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994019321-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1993005020-A1 | INDOLES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530907-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MAP2 3550/4885KDM4E 2163/4885ALDH1A1 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.